UPDATE: The video for this webinar is now available.

I’m pleased to announce two funding opportunity notices that support clinical and translational research (CTR) in Institutional Development Award (IDeA) states: the IDeA Clinical & Translational Research Network (CTR-N) award (PAR-23-241), and the IDeA Clinical & Translational Research Development (CTR-D) award (PAR-23-257). 

These programs support clinical and translational research at IDeA-eligible institutions through programs that develop research infrastructure and human resources, equip investigators and institutions to develop competitive clinical research programs, and strengthen collaborative research that addresses health conditions prevalent in IDeA states. A reissue of PAR-20-175, the CTR-N award continues support for statewide or multistate regional networks in IDeA states that have been conducting significant levels of clinical and translational research. The new CTR-D award supports clinical and translational research, workforce development, and infrastructure enhancement at health research organizations with limited clinical and translational research capacity, to help them build a foundation and enable recipients to conduct research on diseases and health challenges faced by the populations they serve.  

UPDATE: The video from this webinar is now available.

Are you preparing a grant application for the NIH Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) K99/R00 or UE5 programs? If so, please join our webinar to learn more about the programs and application components and to ask questions:

Tuesday, September 12, 1:00-3:00 p.m. ET
Zoom meeting link
Join by phone
Meeting ID: 160 151 7840
Passcode: 249272

UPDATE: The video for this webinar is now available.

We’re pleased to announce that the Centers of Biomedical Research Excellence (COBRE) Phase 3 notice of funding opportunity (NOFO) (PAR-23-216) has been reissued. The COBRE program supports the establishment and development of innovative biomedical and behavioral research centers at Institutional Development Award (IDeA)-eligible institutions. The goal of this NOFO is to solidify the research base built in Phases 1 and 2 through continued support of research and research infrastructure and to implement strategies to sustain research excellence beyond COBRE funding.

Application due date: September 26, 2023
Earliest start date: July 2024

We’re pleased to announce a virtual “office hour” on August 16 for potential applicants for our Bridges to the Baccalaureate (B2B) and Bridges to the Doctorate (B2D) research training programs.

B2B develops a diverse pool of research-oriented undergraduates who transition from associate to baccalaureate degree-granting institutions and complete a baccalaureate STEM degree, positioning them to pursue research-oriented biomedical higher degree programs or enter careers in the biomedical research workforce.
Next application due date: September 25, 2023

UPDATE: Please see the updated post on this topic.

We’re pleased to share that the notice of funding opportunity (NOFO) for the Native American Research Centers for Health (NARCH) program (PAR-23-166) has been reissued. NARCH supports federally recognized American Indian/Alaska Native Tribes and Tribal colleges or universities, Tribal health programs, and Tribal organizations. The program funds health-related research, research career enhancement, and research infrastructure-enhancement activities. This NOFO is led by NIGMS with additional participating NIH institutes, centers, and offices.

A NARCH award is for up to 5 years with an annual budget of up to $1.3 million in direct costs. The first NARCH application due date is July 8, 2024.  

UPDATE: The video for this webinar is now available.

We’re pleased to announce the notice of funding opportunity (NOFO) for our interactive digital media (IDM) program (PAR-23-213). This NOFO supports eligible small business concerns to develop IDM biomedical science resources for pre-college students and teachers. The products should engage users with interactive learning experiences, thus enhancing interest in learning more about biomedical research and in developing problem-solving skills. The first application receipt date is September 5, 2023.

We strongly encourage all interested in applying to attend our upcoming webinar:

UPDATE: The video and slides [PDF] for this webinar are now available.

I’m pleased to announce that the Maximizing Investigators’ Research Award (MIRA) notice of funding opportunity for early stage investigators (ESIs) (PAR-23-145) has been reissued. MIRA funding provides support for an area of research in an ESI’s laboratory that falls within the NIGMS mission. The next application due date is October 3, 2023.

We’re hosting a webinar to discuss the key features of the ESI MIRA program and to answer your questions:

Are you or other principal investigators at your institution preparing a grant application for the NIH Research Enhancement Award (R15)? If so, please join our upcoming webinar, “The NIH Research Enhancement Award (R15) .  .  . What You Need to Know!” to learn about the various NIH R15 programs, which one NIGMS participates in, and application components. You’ll also have the opportunity to ask questions:

Thursday, June 15, 2:30-3:30 p.m. ET
Zoom registration link
Event webpage

We’re pleased to share the notice of funding opportunity (NOFO) (PAR-23-145) to provide sustained support for biomedical research through our Maximizing Investigators’ Research Award (MIRA) (R35) program for early stage investigators (ESIs). This NOFO allows applications from ESIs proposing research within NIGMS' scientific mission.

NIGMS has granted MIRAs to ESIs since Fiscal Year (FY) 2016. We’ve analyzed and published application and funding trends for MIRAs from FY 2019 to FY 2021 and for various funding types, including MIRA, for FY 2022. Changes in this iteration of the NOFO include:

We’re pleased to announce the publication of notice NOT-GM-23-040 introducing a change in the institutional eligibility criteria for applications to our Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20).